<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02899039</url>
  </required_header>
  <id_info>
    <org_study_id>2011-31</org_study_id>
    <secondary_id>RC12_3608</secondary_id>
    <nct_id>NCT02899039</nct_id>
  </id_info>
  <brief_title>Follicular Helper T Cells: Biological Marker and Involvement in the Physiopathology of the IgG4-related Disease</brief_title>
  <acronym>G4-FH</acronym>
  <official_title>Follicular Helper T Cells: Biological Marker and Involvement in the Physiopathology of the IgG4-related Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique Hopitaux De Marseille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique Hopitaux De Marseille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      IgG4-related disease is a rare and very recently identified pathology, whose frequency is
      certainly underestimated.

      The clinical presentation varies among affected organs, and most often, patients have at
      least three organ damage.

      These organs exhibit tissue infiltration mononuclear polymorphic cells with often severe
      fibrosis progression resulting in a loss of function.

      The biomarker, though not specific, is a polyclonal elevated serum IgG4, and histological
      marker, currently held by several teams, is the presence within the inflammatory infiltrate,
      of a predominance of IgG4-expressing plasma-cells with a relative plasma-cells IgG4 + / IgG
      +&gt; 50% on tissue immunostaining.

      The investigators project provides a global assessment of T lymphocyte abnormalities and
      specifically the TFH (Follicular Helper) during this IgG4-related disease compared to
      so-called groups &quot;control&quot; subjects suffering from Sjogren syndrome or healthy subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Follicular Helper T cells (CD4 + CXCR5 + ICOShigh) in the blood</measure>
    <time_frame>36 months</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>IgG4-related Disease</condition>
  <arm_group>
    <arm_group_label>IgG4-related disease</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects suffering from IgG4-related disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sjögren syndrome</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects suffering from Sjôgren syndrome</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy controls</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Healthy subjects</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>extra blood draw samples</intervention_name>
    <arm_group_label>IgG4-related disease</arm_group_label>
    <arm_group_label>Sjögren syndrome</arm_group_label>
    <arm_group_label>Healthy controls</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  IgG4-related disease patients or

          -  Sjogren syndrome patients or

          -  Healthy subjects

        Exclusion Criteria:

          -  Presence of autoimmune or inflammatory associated disease

          -  Age less than 18 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Urielle Desalbres</last_name>
    <role>Study Director</role>
    <affiliation>Assistance Publique Hôpitaux de Marseille</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>APHM</name>
      <address>
        <city>Marseille</city>
        <zip>13</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 2, 2016</study_first_submitted>
  <study_first_submitted_qc>September 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 13, 2016</study_first_posted>
  <last_update_submitted>September 12, 2016</last_update_submitted>
  <last_update_submitted_qc>September 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulin G</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

